Navigation Links
Transport's Phase 2 Data Show Single Treatment SoloVir(TM) ETS Significantly Stops Progression of Cold Sore Episode
Date:11/28/2007

Data Presented Today at the 19th Annual Piper Jaffray Health Care

Conference

FRAMINGHAM, Mass. and NEW YORK, Nov. 28 /PRNewswire/ -- Today at the 19th Annual Piper Jaffray Health Care Conference, Dr. Dennis I. Goldberg, President and Chief Executive Officer of Transport Pharmaceuticals, Inc., presented compelling clinical results of a Phase 2 study designed to evaluate the safety and efficacy of the company's lead drug/device product, the SoloVir(TM) Electrokinetic Transdermal System (SoloVir(TM) ETS) for recurrent herpes labialis (cold sores). SoloVir(TM) ETS uses single-use drug cartridges containing Transport's novel, five-percent acyclovir gel.

This unique study was designed to determine the optimum treatment protocol based upon the immediate delivery of a large bolus of acyclovir into the skin during a herpetic episode, i.e. whether treatment at either the prodrome or erythema stage on day one of the herpetic episode was significantly better than placebo. TPI-H-221 was a multi center, randomized, double blind, placebo-controlled study that enrolled approximately 260 subjects.

Dennis I. Goldberg, President and CEO, commented on the clinical results, "The TPI-H-221 study has demonstrated that treatment at the erythema or papule/edema stages, the first visible signs of a cold sore, decreased the number of patients who progressed to classical lesions, and resulted in a dramatic decrease in healing times. Patients who treated earlier, at the prodrome stage, did not see a statistically significance benefit. Our Phase 2 study provides valuable insights into the treatment of herpes labialis. SoloVir(TM) ETS is the only one time treatment to achieve a statistically significant and clinically meaningful decrease in herpetic lesions. This study provides a number of important findings that provide a clear path for completing the development of this novel combination drug/device product."

Spotswood Sprua
'/>"/>

SOURCE Transport Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... Rio Salado College joined nine educational institutions in Washington D.C., July ... - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the Bill ... hosted by EDUCAUSE and NGLC, which is designed to bring leadership teams of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... ... alcohol abuse, or those who might personally be struggling with chemical dependency, may ... post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Harbor Laboratory (CSHL) has demonstrated for the first time ... can initiate signaling that regulates both the structure and ... suggests a significant role for this class of receptors ... but also in cognition and in pathological processes in ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... Controlling heart rate is key when heart failure, irregular ... News) -- When added to heart failure, the irregular ... , Now, an international study shows that a ... best first option for keeping patients healthy under these ...
... HILL, N.C., June 18 A CI head once ... have it, but the only,time you realize you need ... In today,s marketing space, most companies need competitive,intelligence to ... the key insights are lacking that people begin to ...
... Prevent Skin Cancer, HOUSTON, June 18 Now that ... us, the cancer care experts at Texas Oncology remind,Texans to ... Although the most prevalent cancer in the United States today,skin ... more than 1,million annual U.S. cases of skin cancer are ...
... List from a ... Worldwide Field of 5,000, PHILADELPHIA, June ... of SCA Personal Care, from among,5,000 companies for inclusion in its ... think-tank dedicated to the research and,promotion of profitable best practices in ...
Cached Medicine News:Health News:Neuroscientists show insulin receptor signaling regulates structure of brain circuits 2Health News:Neuroscientists show insulin receptor signaling regulates structure of brain circuits 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2Health News:Texas Oncology Urges Texans to 'Save Your Skin' 2Health News:Texas Oncology Urges Texans to 'Save Your Skin' 3Health News:Ethisphere Institute Names SCA to List of Top Ethical Companies 2
(Date:8/28/2015)...  With the heroin epidemic in the ... Jacksonville -based Lakeview Health drug and alcohol treatment ... explain why fentanyl is causing a new wave of ... more potent than pharmaceutical grade heroin and often illegally ... of death skyrockets. "Fentanyl can be an ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
Medicine Products: